Equity Profile
Pre-Earnings Brief
Zai Lab Limited is a biotechnology company focused on developing innovative medicines for patients with unmet medical needs. Operating in the healthcare sector, Zai Lab is significant as it aims to address critical health challenges, particularly in oncology and autoimmune diseases.
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
Revenue growth reflects the company's ability to expand its market presence and commercialize its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
50%
Avg EPS Surprise
+1.30%
Avg Stock Reaction
-2.39%
In the last quarter, Zai Lab reported an EPS of -$0.46, slightly missing expectations. The stock reacted positively the following day, gaining 1.55%.
Management Promises & Guidance
Investors are anticipating Zai Lab's upcoming earnings report with caution, given its mixed performance in previous quarters. The lack of analyst estimates adds uncertainty to market expectations.
Bull Case
If Zai Lab can demonstrate improved financial metrics or positive developments in its drug pipeline, it could lead to a significant stock rally.
Bear Case
Conversely, if the company reports larger-than-expected losses or delays in product development, it could lead to a sharp decline in stock price.
Earnings Per Share (EPS)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/ARevenue growth reflects the company's ability to expand its market presence and commercialize its products.
Expectations
The print will turn on these two things.
Q1
What will be the EPS for Q1-2026?
The EPS figure will be crucial in assessing the company's profitability and could significantly influence investor sentiment.
Q2
How is Zai Lab progressing with its drug pipeline?
Updates on the drug pipeline will provide insights into future revenue potential and the company's growth trajectory.
Edge
Why consensus could be wrong
The Street may be overly cautious given Zai Lab's recent performance, underestimating potential positive developments in its drug pipeline.
Supporting Evidence
The options market is pricing a 20.11% move, indicating expectations for significant volatility that may not align with historical trends.
Zai Lab has a 50% EPS beat rate, suggesting that positive surprises are as likely as negative ones.
Key Risk
If the EPS comes in better than -$0.40, it could challenge the current cautious sentiment.
Edge
Pre-commit to what would confirm each case.
This quarter's performance will be closely scrutinized as it follows a pattern of mixed results, and the market is eager for signs of improvement.
Bull Confirmed If
A narrower EPS loss than -$0.40 would indicate stronger operational performance.
Bear Confirmed If
An EPS loss greater than -$0.50 would raise concerns about the company's financial health.
Pre-Earnings Positioning
Implied Move
±20.11%
Historical Avg
±4.5%
The options market is pricing in a significant move, indicating that investors expect volatility around the earnings announcement.
Options are pricing ±17.8% while ZLAB has averaged ±4.5% over the last 8 prints — setup is pricing rich.
ATM IV
0.7%
30d HV
59.7%
Edge
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
n=30Fade rate: 10 of 26 (38%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 26 (62%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.7% (modestly positive historical bias).
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Zai Lab beats expectations, history suggests the stock could rise by about 4.5%, confirming a positive trend.
In-Line / Cautious
If results are in line with expectations, the stock may see a muted reaction, reflecting ongoing investor caution.
Miss
Should the company miss expectations, history indicates a potential drop of around 1.1%, which could further shake investor confidence.
Preparation
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
Corporación América Airports S.A.